ストックスクリーナーアプリを入手
26.63
0.41%
0.11
前日終値:
$26.52
開ける：
$26.55
24時間の取引高:
530.03K
Relative Volume:
0.65
時価総額：
$1.73B
収益：
-
当期純損益:
$-107.85M
株価収益率:
-12.05
EPS:
-2.21
ネットキャッシュフロー:
$-106.82M
1週間 パフォーマンス:
-1.66%
1か月 パフォーマンス:
-9.45%
6か月 パフォーマンス:
-38.70%
1年 パフォーマンス:
-38.24%
1日の値動き範囲:
$26.07
$26.89
1週間の範囲:
$25.55
$27.71
52週間の値動き範囲:
$25.55
$51.61
Vera Therapeutics Inc Stock (VERA) Company Profile
名前
Vera Therapeutics Inc
セクター
電話
650-770-0077
住所
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
VERA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
26.63 | 1.73B | 0 | -107.85M | -106.82M | -2.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-04 | 開始されました | Wolfe Research | Outperform |
| 2025-01-28 | 開始されました | Goldman | Buy |
| 2024-11-21 | 開始されました | Wells Fargo | Overweight |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-01-25 | 開始されました | Oppenheimer | Outperform |
| 2024-01-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-12-18 | 開始されました | Raymond James | Outperform |
| 2023-11-10 | アップグレード | Jefferies | Hold → Buy |
| 2023-08-16 | 開始されました | Guggenheim | Buy |
| 2023-01-04 | ダウングレード | Jefferies | Buy → Hold |
| 2023-01-04 | ダウングレード | Wedbush | Outperform → Neutral |
| 2022-07-12 | 開始されました | JP Morgan | Overweight |
| 2022-05-02 | 開始されました | H.C. Wainwright | Buy |
| 2022-04-19 | 開始されました | Wedbush | Outperform |
すべてを表示
Vera Therapeutics Inc (VERA) 最新ニュース
69,724 Shares in Vera Therapeutics, Inc. (NASDAQ:VERA) Bought by Raymond James Financial Inc. - Defense World
Vera Therapeutics stock hits 52-week low at $25.97 - Investing.com
Vera Therapeutics validates Fair Value bearish call with 42% decline By Investing.com - Investing.com UK
Swiss National Bank Purchases 15,700 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
AlphaQuest LLC Takes Position in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Acquires 7,895 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Is Vera Therapeutics (NASDAQ:VERA) Weighed On By Its Debt Load? - Simply Wall St
Victory Capital Management Inc. Increases Stake in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of “Buy” by Analysts - Defense World
Vera Therapeutics (VERA) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Growth Accelerates: 9 Strategic Hires Secure Equity Package Worth $2.3M - StockTitan
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MENAFN.COM
What is HC Wainwright’s Estimate for VERA FY2025 Earnings? - Defense World
Vera Therapeutics: Does The Earlier Otsuka Launch Harm Its Prospects Much? - Seeking Alpha
Cantor Fitzgerald Analysts Lower Earnings Estimates for VERA - Defense World
JPMorgan Chase & Co. Has Lowered Expectations for Vera Therapeutics (NASDAQ:VERA) Stock Price - Defense World
Vera Therapeutics (NASDAQ:VERA) Price Target Cut to $71.00 by Analysts at JPMorgan Chase & Co. - Armenian Reporter
Vera Therapeutics Getting Closer To Key Technical Benchmark - MSN
Rhumbline Advisers Has $2.48 Million Position in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Q1 EPS Estimates for Vera Therapeutics Boosted by Wedbush - Defense World
(VERA) On The My Stocks Page - Stock Traders Daily
What is Wedbush’s Forecast for VERA FY2029 Earnings? - Defense World
Guggenheim Raises Vera Therapeutics (NASDAQ:VERA) Price Target to $61.00 - Defense World
Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - GlobeNewswire
Wedbush Adjusts Price Target on Vera Therapeutics to $34 From $38, Maintains Neutral Rating - Marketscreener.com
Guggenheim raises Vera Therapeutics stock target to $61 - Investing.com India
Can Vera Therapeutics Reveal New Immunology Pipeline Updates at Upcoming TD Cowen Conference? - StockTitan
Optimistic Buy Rating for Vera Therapeutics: Strong Financials and Promising Pipeline Drive Positive Outlook - TipRanks
Vera Therapeutics targets Q2 for IgAN drug results, FDA filing By Investing.com - Investing.com South Africa
Vera Therapeutics 2024 Loss Widens -February 26, 2025 at 08:53 am EST - Marketscreener.com
Vera Therapeutics targets Q2 for IgAN drug results, FDA filing - Investing.com India
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Earnings Flash (VERA) Vera Therapeutics Posts Full Year 2024 Total Operating Expenses $167.2M - Marketscreener.com
Earnings Flash (VERA) Vera Therapeutics Posts Full Year 2024 Net Loss $-2.75 a Share, vs. FactSet Est of $-2.90 Loss - Marketscreener.com
Vera Therapeutics, Inc. Reports 2024 Business Highlights and Financial Results; On Track for Phase 3 ORIGIN Trial Results and FDA Submission for Atacicept in IgA Nephropathy - Nasdaq
Can Vera's Breakthrough IgAN Therapy Disrupt the $5B Kidney Disease Market? Phase 3 Results Coming Q2 2025 - StockTitan
Vera Therapeutics’ Atacicept Positioned for Growth Amid Market Overreaction to Otsuka’s Sibeprenlimab - TipRanks
(VERA) Trading Advice - Stock Traders Daily
Vera Therapeutics Inc (VERA) may enjoy gains as insiders got busy in the recent days - Knox Daily
Cantor Fitzgerald maintains Overweight on Vera Therapeutics stock By Investing.com - Investing.com Nigeria
Evercore ISI maintains Vera Therapeutics stock with $75 target By Investing.com - Investing.com Canada
Evercore ISI maintains Vera Therapeutics stock with $75 target - Investing.com
Vera Therapeutics weakness on Otsuka plans ‘makes no sense,’ says Wells Fargo - MSN
Vera Therapeutics stock drops amid rival drug update - MSN
Vera Therapeutics (NASDAQ:VERA) Hits New 1-Year LowWhat's Next? - MarketBeat
Vera Therapeutics stock drops amid rival drug update By Investing.com - Investing.com Australia
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Vera plunges as Otsuka updates on rival therapy - MSN
Vera Therapeutics Inc (VERA) 財務データ
収益
当期純利益
現金流量
EPS
Vera Therapeutics Inc (VERA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Fordyce Marshall | PRESIDENT AND CEO |
Feb 26 '25 |
Sale |
27.65 |
9,075 |
250,882 |
204,665 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):